Abstracts tagged "chemokines"

Abstract Number: 1028 • 2014 ACR/ARHP Annual Meeting
ADAM-10 Plays Monocyte Migration and Adhesion in Rheumatoid Arthritis Synovial Fibroblasts
Takeo Isozaki^1,2, Sho Ishii², Shinichiro Nishimi², Airi Maeoka², Mayu Saito², Nao Oguro², Shinya Seki², Yoko Miura², Yusuke Miwa², Koei Oh³, Yoichi Toyoshima³, Masanori Nakamura³, Katsunori Inagaki³ and Tsuyoshi Kasama², ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ³Department of Orthopedics, Showa University School of Med, Tokyo, Japan
Background/Purpose :A disintegrin and metalloprotease family proteins (ADAMs) have been reported to be involved in a number of inflammatory conditions. We previously reported that ADAM-10…
Abstract Number: 922 • 2014 ACR/ARHP Annual Meeting
A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain
Rachel E. Miller¹, Shingo Ishihara², Phuong Tran³, Richard J. Miller⁴ and Anne-Marie Malfait⁵, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁵Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose - Damage associated molecular patterns (DAMPs) result from cellular stress and extracellular matrix breakdown. They may contribute to osteoarthritis (OA) pathogenesis by promoting synovitis…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 642 • 2013 ACR/ARHP Annual Meeting
Serum Concentrations Of Type I Interferon-Regulated Chemokines Are Associated With Disease Activity In Systemic Lupus Erythematosus
Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Expression array studies suggest the activity of Type I interferon (IFN), as reflected in IFN-induced genes, is associated with phenotypic subsets in SLE. Three…
Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Melissa E. Munroe¹, Jourdan R. Anderson², Krista M. Bean³, Joan T. Merrill⁴, Joel M. Guthridge³, Virginia C. Roberts³, Linda F. Thompson^5,6 and Judith A. James^4,7, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
Abstract Number: 558 • 2013 ACR/ARHP Annual Meeting
Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice
Shuzo Sato¹, Sarah Williams², Eva Karam³ and Xian Zhang⁴, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VA Medical Center, Charleston, SC, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC
Background/Purpose: Fli-1 expression level, a member of the Ets family of transcription factors, is a mitigating factor in the development of nephritis in murine models…
Abstract Number: 81 • 2013 ACR/ARHP Annual Meeting
Synovial Expression Of CCL19, MCP-1, and Their Receptors In Patients With Meniscal Injury: Variability and Relationship With Knee Symptoms
Justin B. Gan¹, Anjali Nair², Kanta Saha¹, Nikhil Verma³, Charles Bush-Joseph³, Matthew Tetreault³, Anne-Marie Malfait⁴, Kumar B. Rajan⁵ and Carla R. Scanzello¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Orthopedics, Rush University Medical Center, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL, ⁵Department of Internal Medicine, Biostatistics, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with meniscal injury are at increased risk for symptomatic knee osteoarthritis (OA), and often already have intraoperative signs of early-stage cartilage degradation. We…
Abstract Number: L2 • 2013 ACR/ARHP Annual Meeting
Proteome-Wide Analysis and CXCL4 As a Pathogenic Biomarker in Systemic Sclerosis
Timothy Radstake¹, Lenny van Bon², Alsya Affandi¹, Jasper Broen³, Romy Christmann⁴, Lukasz Stawski⁵, Giuseppina Farina⁶, Allison Mathes⁷, Marta Cossu⁸, MArk Wenink⁹, Roger Hesselstrand¹⁰, Tore Saxne¹¹, Dirk Wuttge¹⁰, John D. Reveille¹², Shervin Assassi¹², Maureen D. Mayes¹³, Wim B van den Berg¹⁴, Vanessa Smith¹⁵, Filip De Keyser¹⁵, Claudio Lunardi¹⁶, Piet L.C. Van Riel¹⁷, Madelon C. Vonk¹⁸, Lorenzo Beretta¹⁹, Maria Trojanowska²⁰ and Robert Lafyatis⁴, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht/Radboud University Nijmegen Medical Center, Utrecht/Nijmegen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Rheumatology, Boston Medical Center, Boston, MA, ⁶Arthritis center, Boston University, Boston, MA, ⁷rheumatology, Boston Medical Center, boston, MA, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, utrecht, Netherlands, ⁹rheumatology and Clinical Immunology, university Medical Center Utrecht, utrecht, Netherlands, ¹⁰Rheumatology, Lund University, Lund, Sweden, ¹¹Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ¹²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas Health Science Center at Houston, Houston, TX, ¹⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ¹⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ¹⁶Department of Medicine, Università degli Studi di Verona, Verona, Italy, ¹⁷Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁸Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁰Arthritis Center, Boston University, Boston, MA
Background/Purpose: We hypothesized that plasmacytoid dendritic cells are implicated in the pathogenesis of systemic sclerosis via mechanisms beyond previously suggested type I interferon production. Methods:…
Abstract Number: 2822 • 2013 ACR/ARHP Annual Meeting
IKKε Deficiency Prolongs Neutrophil Survival Paradoxically Prolonging Inflammation In The Absence Of a Type I Interferon Response
Maripat Corr¹, Christopher Chung², Seong-Kyu Kim³, D. L Boyle⁴ and G. S. Firestein⁵, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Deficiency of the IKK-related kinases IKKε synergizes with the anti-inflammatory effects of IFNß in a murine model of arthritis., and this effect is mediated…
Abstract Number: 2495 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Protective Endoplasmic Reticulum Aminopeptidase 1 Variants Lead To Decreased Natural Killer Cell Conjugation and Activation
Hasan Abdullah¹, Zhenbo Zhang², Robert Inman³ and Nigil Haroon⁴, ¹IMS, University of Toronto, Toronto, ON, Canada, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory arthritis affecting the axial and peripheral joints. Human Leukocyte Antigen (HLA)-B27 and Endoplasmic Reticulum Aminopeptidase (ERAP) 1 genes…
Abstract Number: 2404 • 2013 ACR/ARHP Annual Meeting
CXCL13-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset
Shio Kobayashi¹, Koichi Murata², Hideyuki Shibuya², Masahiro Ishikawa², Moritoshi Furu³, Hiromu Ito³, Shuichi Matsuda², Takeshi Watanabe⁴ and Hiroyuki Yoshitomi⁵, ¹Center for Innovation in Immunoregulative Technology ant Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Ectopic lymphoid structures are frequently formed in synovial tissues of patients with rheumatoid arthritis (RA). Several reports suggested that CD4 T-cells have a crucial…
Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 1602 • 2013 ACR/ARHP Annual Meeting
Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Hilda Fragoso-Loyo¹, Alí Duarte-García², Sandra Juárez-Arellano³, Alba Cicero-Casarrubias⁴, Juanita Romero-Díaz⁵, Luis LLorente-Peters¹ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: The nature and pathogenesis and cognitive dysfunction (CD) in patients with SLE is unkown.To determine the presence and levels of autoantibodies, cytokines and chemokines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].